According to the latest report published by Credence Research, Inc. “Liquid Biopsy Market – Growth, Future Prospects, and Competitive Analysis, 2016-2022,” The market for liquid biopsy was valued at USD 1,881.9 million in 2015 and is expected to reach USD 10,850.3 million by 2022, increasing to CAGR by 24.7 percent from 2016 to 2022.
Market Insights
In the past, tissue samples extracted by biopsy have been evaluated to detect malignancy. However, some micrographs have produced inconsistent and ambiguous results, requiring repeated procedures. The advent of molecular diagnostics and next-generation sequencing provided pathologists with a powerful tool for effective diagnosis. Even with these advances, the diagnosis of cancer remained subject to a restriction on the availability of biopsy tissue, which also posed a challenge in the case of successful monitoring of therapy. However, the eventual advent of liquid biopsy overcame this constraint by the efficient use of accurate circulating tumor cells (CTCs) for detection and isolation.
Browse Full Report Originally Published by Credence Research at https://www.credenceresearch.com/report/liquid-biopsy-market
In the recent period, the range of liquid biopsy tools has been extended to include circulating tumor DNA (ctDNA) and extracellular vesicles (EVs). DNA contains a small fraction of the patient’s cell-free DNA; it can be easily evaluated for genetic inconsistency using target amplification and sequencing tools. In addition, EVs are currently the latest addition to the portfolio of liquid biopsies. EVs provide easy access to biomolecule subsets in whole cells. The technology-based on EVs focuses on the identification of mutations in mRNA.
Extensive research has been carried out in recent years on the development of sophisticated analytical tools for cancer cell analysis to detect genetic variation at low allele frequency. The CTCs are the first of these liquid biopsy units. However, the advent of easy isolation of cell-free DNA has provided vital insights that move a step ahead of CTCs. The latest tools for the analysis of EVs are rapidly gaining importance on the basis of their potential ability to identify genetic variation. The latest CTC technologies use EpCAM protein for immune capturing, but this tool demonstrates reduced expression during epithelial to mesenchymal transition. Other isolation techniques are heavily dependent on cell size, cellular behavior in electrical fields, morphology, and deformity. The scarcity of CTCs in blood has encouraged researchers to develop advanced methods for obtaining molecular information from single cells, thus increasing their potential for use in monitoring therapy.
As the commercial interest in this field is on the rise, several major diagnostics and medical technology companies have ventured into this market. In addition, there is also a significant increase in the number of start-ups specializing in the field. Industry giants are striking deals with pharmaceutical and biotech companies to expand the applications of liquid biopsy.
Company Profiles
- Myriad Genetics
- Oncocyte
- RainDance Technologies
- Veracyte
- Foundation Medicine
- Genomic Health
- Biocept
- Natera
- Qiagen
- Trovagene
- Others
You can get the sample copy of this research by Credence Research here: https://www.credenceresearch.com/sample-request/57830
Report Scope by Segments
By Type
- Circulating Tumor Cells (CTCs)
- Circulating Tumor DNA (ctDNA) Fragments
- Extracellular Vesicles (EVs)
By Application Type
- Prognosis
- Diagnosis
- Therapy monitoring
- Others
By Geography Segment
- North America (the U.S., Rest of North America)
- Europe (U.K., Germany, France, Rest of Europe)
- Asia Pacific (China, Japan, India, Rest of Asia Pacific)
- Rest of the World (the Middle East & Africa, Latin America)
No comments:
Post a Comment